FDA to expedite review of Lilly's gastric cancer drug

10/25/2013 | Pharmaceutical Business Review Online

The FDA granted priority-review designation to Eli Lilly & Co.'s biologics license application for ramucirumab, or IMC-1121B, for treatment of patients with advanced gastric cancer whose disease progressed after initial chemotherapy. The drug is also under regulatory review in Europe.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI